Micron Technology
MU
NVIDIA
NVDA
Intel
INTC
Adobe
ADBE
Salesforce
CRM
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 29.340
- +0.940+3.31%
Close Dec 20 16:00 ET
- 29.340
- 0.0000.00%
Post 16:11 ET
2.05BMarket Cap-7.76P/E (TTM)
29.770High28.090Low1.56MVolume28.090Open28.400Pre Close45.63MTurnover2.84%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High2.77P/B1.61BFloat Cap15.32052wk Low--Dividend TTM54.91MShs Float58.380Historical High--Div YieldTTM5.92%Amplitude7.520Historical Low29.249Avg Price1Lot Size
Akero Therapeutics News
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Akero Therapeutics Analyst Ratings
Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities
Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics
BofA Securities Initiates Akero Therapeutics(AKRO.US) With Hold Rating
Bank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
LifeSci Capital Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $60
Buy Rating Reaffirmed for Akero Therapeutics: Strong Financials and Promising Clinical Trials Bolster Confidence
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.